<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011737</url>
  </required_header>
  <id_info>
    <org_study_id>SMC2013-08-066</org_study_id>
    <nct_id>NCT02011737</nct_id>
  </id_info>
  <brief_title>Naftopidil 75mg for Improving Clearance of Urinary Stones</brief_title>
  <official_title>The Effectiveness and Safety of Naftopidil 75mg for Improving Clearance of Ureteral and Renal Stones After Shockwave Lithotripsy: Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Efficacy and Safety of oral intake of Naftopidil
      75mg once daily for the improving clearance of ureteral or renal stones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, Single-center, Double blind, Randomized controlled trial

      Treatment

      - Oral Naftopidil 75 mg once daily are given to the patients who are scheduled for shockwave
      lithotripsy (ESWL) because of ureteral or renal stones.

      Follow up Assessments including X-ray(KUB), visual analogue pain scale, are done 2, 4, and 6
      weeks after the ESWL.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of the treatment success rate in two weeks after ESWL between treatment group and placebo group</measure>
    <time_frame>2 weeks after ESWL</time_frame>
    <description>Treatment success is defined as no or less than 3 mm size remnant stone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of the treatment success rate after ESWL between treatment group and placebo group</measure>
    <time_frame>4, 6 weeks after ESWL</time_frame>
    <description>Treatment success is defined as no or less than 3 mm size remnant stone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>2,4,6weeks</time_frame>
    <description>Rate of total Adverse Events and Adverse Events relevant to Investigational drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>baseline, 2, 4, 6 weeks</time_frame>
    <description>visual analogue pain scale due to urinary stone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of additional intervention</measure>
    <time_frame>6 week</time_frame>
    <description>incidence of additional intervention for the urinary stone ex&gt; ureteral stent insertion, percutaneous nephrostomy, ureteroscopic ureterolithotomy, percutaneous nephrolithotomy, laparoscopic stone removal and so on</description>
  </secondary_outcome>
  <other_outcome>
    <measure>time to stone expulsion</measure>
    <time_frame>2,4,6week</time_frame>
    <description>the time (days) elapsed from first ESWL to the expulsion of the stone</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of ESWL</measure>
    <time_frame>6week</time_frame>
    <description>The number of required ESWL for the stone expulsion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Kidney Calculi</condition>
  <condition>Ureter Calculi</condition>
  <arm_group>
    <arm_group_label>Naftopidil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naftopidil 75mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naftopidil 75mg</intervention_name>
    <arm_group_label>Naftopidil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radio-opaque (identifiable in KUB) ureter or kidney calculi

          -  size criteria is from 5mm to 15mm

        Exclusion Criteria:

          -  Symptomatic acute urinary tract infection during the run-in period

          -  severe hydronephrosis

          -  2 or more urinary stones

          -  Radiolucent (non-visible in KUB) stone

          -  recent intervention for the urinary stone within 6 month

          -  Patients who have ureteral stent

          -  over 2.0 mg/dl of serum creatinine level

          -  severe hepatic dysfunction

          -  orthostatic hypotension

          -  current usage of alpha-adrenergic blocker or calcium channel blocker

          -  Pregnant or nursing women

          -  Age under 15 year

          -  severe or uncontrolled medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deok Hyun Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deok Hyun Han, MD</last_name>
    <phone>82-2-3410-6431</phone>
    <email>deokhyun.han@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deok Hyun Han, M.D.</last_name>
      <phone>+82-10-9933-5125</phone>
      <email>deokhyun.han@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Deok Hyun Han, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seol Ho Choo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>HAN, DEOK HYUN</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Medical Expulsive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

